Goserelin implant - AMW

Drug Profile

Goserelin implant - AMW

Latest Information Update: 05 Aug 2016

Price : $50

At a glance

  • Originator AMW GmbH
  • Class Antineoplastics; Oligopeptides; Pituitary hormone releasing hormones
  • Mechanism of Action Gonadotropin releasing hormone stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Registered Breast cancer; Endometriosis; Female infertility; Prostate cancer; Uterine diseases; Uterine leiomyoma

Most Recent Events

  • 25 May 2016 AMW completes a phase III trial for Prostate cancer in Germany (EudraCT2014-002484-15)
  • 16 Mar 2016 Chemical structure information added
  • 15 Mar 2016 Biomarkers information updated
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top